CY1106576T1 - Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας - Google Patents

Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας

Info

Publication number
CY1106576T1
CY1106576T1 CY20071100631T CY071100631T CY1106576T1 CY 1106576 T1 CY1106576 T1 CY 1106576T1 CY 20071100631 T CY20071100631 T CY 20071100631T CY 071100631 T CY071100631 T CY 071100631T CY 1106576 T1 CY1106576 T1 CY 1106576T1
Authority
CY
Cyprus
Prior art keywords
pyrrolidin
treatment
migraine
substituted
disease
Prior art date
Application number
CY20071100631T
Other languages
English (en)
Inventor
Corinna Sundermann
Bernd Sundermann
Helmut Buschmann
Hagen-Heinrich Hennies
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1106576T1 publication Critical patent/CY1106576T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Abstract

Η εφεύρεση αφορά υποκατεστημένα παράγωγα 2-πυρρολιδιν-2-υλ-1Η-ινδόλης του τύπου (I), μεθόδους για την παρασκευή τους, φάρμακα, τα οποία περιέχουν τις ενώσεις αυτές, και τη χρησιμοποίηση των παραγώγων 2-πυρρολιδιν-2-υλ-1 Η-ινδόλης για την παρασκευή ενός φαρμάκου για την αναστολή ΝΟ-συνθάσης και για την θεραπεία ημικρανίας, σηπτικού σοκ, πολλαπλής σκλήρυνσης, νόσου Parkinson, νόσου Alzheimer, νόσου Huntington, φλεγμονών, άλγους φλεγμονών, εγκεφαλικής ισχαιμίας, διαβήτη, μηνιγγίτιδας, αρτηριοσκλήρωσης και/ή για την θεραπεία τραυμάτων.
CY20071100631T 2001-12-06 2007-05-10 Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας CY1106576T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159922A DE10159922A1 (de) 2001-12-06 2001-12-06 Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
PCT/EP2002/013613 WO2003048156A1 (de) 2001-12-06 2002-12-02 Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne

Publications (1)

Publication Number Publication Date
CY1106576T1 true CY1106576T1 (el) 2012-01-25

Family

ID=7708242

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100631T CY1106576T1 (el) 2001-12-06 2007-05-10 Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας

Country Status (18)

Country Link
US (1) US7271192B2 (el)
EP (1) EP1451177B1 (el)
JP (1) JP4663982B2 (el)
AR (1) AR037707A1 (el)
AT (1) ATE357441T1 (el)
AU (1) AU2002363859B2 (el)
CA (1) CA2469346C (el)
CY (1) CY1106576T1 (el)
DE (2) DE10159922A1 (el)
DK (1) DK1451177T3 (el)
ES (1) ES2284973T3 (el)
HU (1) HUP0402283A3 (el)
MX (1) MXPA04005139A (el)
PE (1) PE20030748A1 (el)
PL (1) PL371270A1 (el)
PT (1) PT1451177E (el)
SI (1) SI1451177T1 (el)
WO (1) WO2003048156A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385702T3 (es) 2005-06-07 2012-07-30 Kyowa Hakko Kirin Co., Ltd. Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CN112010841A (zh) * 2020-08-20 2020-12-01 上海体育学院 一种基于吲哚骨架的吡咯烷衍生物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3506683A (en) * 1963-10-07 1970-04-14 Upjohn Co 3-(2-pyrrolidinylidene)-3h-indoles
ES2143992T3 (es) * 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
GB9523999D0 (en) * 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
KR20030060904A (ko) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체

Also Published As

Publication number Publication date
ES2284973T3 (es) 2007-11-16
EP1451177A1 (de) 2004-09-01
DK1451177T3 (da) 2007-07-02
PT1451177E (pt) 2007-04-30
JP2005511694A (ja) 2005-04-28
WO2003048156A1 (de) 2003-06-12
PL371270A1 (en) 2005-06-13
PE20030748A1 (es) 2003-09-05
US20050014815A1 (en) 2005-01-20
AU2002363859A1 (en) 2003-06-17
CA2469346C (en) 2010-10-19
US7271192B2 (en) 2007-09-18
DE10159922A1 (de) 2003-06-26
CA2469346A1 (en) 2003-06-12
HUP0402283A2 (hu) 2005-02-28
ATE357441T1 (de) 2007-04-15
JP4663982B2 (ja) 2011-04-06
AU2002363859B2 (en) 2008-09-18
HUP0402283A3 (en) 2009-07-28
SI1451177T1 (sl) 2007-08-31
EP1451177B1 (de) 2007-03-21
MXPA04005139A (es) 2004-08-11
AR037707A1 (es) 2004-12-01
DE50209798D1 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
SE0102299D0 (sv) Compounds
SE0102300D0 (sv) Compounds
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
EA200401114A3 (ru) Замещённые гидроксиэтиламины
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
SE0101082D0 (sv) Novel use
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
SE0002739D0 (sv) New use
SE0004827D0 (sv) Therapeutic compounds
HUP0303181A2 (hu) 4-Foszfodiészteráz típusú inhibitorok alkalmazása miokardiális betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
EA200100876A2 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
UY27311A1 (es) Agentes antibacterianos
PA8557301A1 (es) Compuestos retinoides heterociclicos